Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Operating Expenses (2016 - 2025)

Cytosorbents' Operating Expenses history spans 15 years, with the latest figure at $11.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $11.2 million for Q4 2025, up 15.95% from a year ago — trailing twelve months through Dec 2025 was $41.2 million (changed 0.24% YoY), and the annual figure for FY2025 was $41.2 million, changed 0.24%.
  • Operating Expenses for Q4 2025 was $11.2 million at Cytosorbents, up from $9.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $17.2 million in Q4 2021 to a low of $9.5 million in Q3 2025.
  • The 5-year median for Operating Expenses is $12.4 million (2022), against an average of $12.2 million.
  • The sharpest move saw Operating Expenses skyrocketed 44.66% in 2021, then plummeted 34.1% in 2024.
  • Year by year, Operating Expenses stood at $17.2 million in 2021, then fell by 29.66% to $12.1 million in 2022, then rose by 20.88% to $14.6 million in 2023, then plummeted by 34.1% to $9.6 million in 2024, then increased by 15.95% to $11.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $11.2 million, $9.5 million, and $10.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.